In Vitro Efficacy Testing Services for Esophageal Cancer

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Esophageal Cancer. Our service offers comprehensive assays to evaluate compound efficacy, mechanism of action, and target engagement in cellular and molecular models relevant to esophageal cancer. Key targets include immune checkpoint proteins such as PD1 and PDL1, along with critical signaling pathways implicated in tumor proliferation, immune evasion, and drug resistance. Our platforms support the investigation of tumor cell viability, immune modulation, and molecular interactions underlying esophageal cancer pathology.

We offer a diverse portfolio of in vitro testing methods, including cell-based assays, biochemical assays, binding kinetics, and advanced fluorescence and luminescence techniques. These methods enable the assessment of compound efficacy, target engagement, and immune interactions to support preclinical drug development for esophageal cancer.

ATP assay: Quantifies cellular ATP levels as a direct measure of cell viability and metabolic activity, indicating cytotoxic or cytostatic effects of tested compounds.

ATP assay (at 0.01 mM): Evaluates compound effects on cell viability at low concentration, useful for determining potency and therapeutic window.

ATP assay (at 1 mM): Assesses compound-induced cytotoxicity at higher concentration, informing on toxicity profiles.

Biolayer interferometry assay: Measures real-time binding interactions between biomolecules, providing kinetic data on drug-target engagement.

Bioluminescence resonance energy transfer (BRET) assay: Detects protein-protein interactions and signaling events in live cells, useful for mechanism-of-action studies.

CHO-K1 Chinese hamster ovary cells transfected with PDL1: Cell-based model to study immune checkpoint interactions and evaluate immunotherapy candidates.

CHO-K1 Chinese hamster ovary cells transfected with PDL1/OKT3: Enables assessment of T-cell mediated immune responses involving PDL1 and OKT3.

CHO-K1 Chinese hamster ovary cells transfected with human CD274/aAPC: Facilitates evaluation of human immune checkpoint pathways and antigen presentation.

Cells transfected with PD1/NFAT/luciferase: Reporter assay to monitor T-cell activation and PD1 signaling modulation.

Chemiluminescent assay: Sensitive detection of proteins or small molecules via enzyme-catalyzed light emission, aiding quantification of target analytes.

Competitive binding assay (with CD274): Measures the ability of compounds to inhibit ligand-receptor interactions, important for evaluating antagonist efficacy.

Dissociation enhanced lanthanide fluorescent immunoassay (DELFIA): Time-resolved fluorescence assay for high-sensitivity detection of biomolecular interactions.

ELISA assay: Quantitative immunoassay for detecting proteins and biomarkers associated with esophageal cancer progression and therapy response.

Flow cytometry assay: Multiparametric analysis of cell populations, enabling detailed profiling of cell surface markers and functional responses.

Fluorescence resonance energy transfer (FRET) assay: Measures molecular proximity and interaction dynamics, supporting mechanistic studies.

Fluorescent assay: General fluorescence-based detection for quantifying cellular or molecular events relevant to drug efficacy.

Fluorescent-activated cell sorting (FACS) assay: Enables isolation and analysis of specific cell subpopulations based on surface markers, supporting biomarker and functional studies.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Combines FRET with time-resolved measurement for sensitive detection of biomolecular interactions.

Jurkat human T-cell leukemia cells transfected with PD1/NFAT/luciferase: T-cell-based reporter system to study immune checkpoint inhibition and T-cell activation.

Jurkat human T-cell leukemia cells transfected with human PD1/NFAT/luciferase: Provides a humanized cell model to assess immunotherapeutic compounds targeting PD1 pathways.

Poly(glutamine/tyrosine) peptide as substrate: Used in enzymatic assays to evaluate protease or kinase activity relevant to cancer signaling.

Surface plasmon resonance assay: Real-time, label-free analysis of biomolecular binding kinetics, supporting drug-target interaction studies.

Our in vitro platforms measure key pharmacological parameters such as potency, efficacy, and binding affinity, which are essential for candidate selection and optimization. These quantitative metrics provide critical information about compound activity, specificity, and therapeutic potential in esophageal cancer models.

EC-50: The concentration of a compound that produces half-maximal efficacy, indicating its functional potency.

IC-50: The concentration required to inhibit a specific biological or biochemical function by 50%, widely used to assess inhibitor potency.

Kd: The equilibrium dissociation constant reflecting the binding affinity between a drug and its target; lower Kd indicates stronger binding.

Ki: The inhibition constant representing the binding affinity of an inhibitor for its target, crucial for understanding competitive interactions.

MEC: Minimum effective concentration at which a compound elicits a measurable biological effect, informing on dosing thresholds.

MIC: Minimum inhibitory concentration required to prevent growth of organisms or cells, relevant for cytostatic and antimicrobial studies.

pIC-50: The negative logarithm of IC-50, providing a standardized scale for comparing inhibitor potencies across compounds.

Recommended In Vitro Efficacy Tests

Atp Binding Cassette Subfamily B Member 1

ATP Binding Cassette Subfamily B Member 1 (ABCB1) is linked to multidrug resistance in esophageal cancer by actively effluxing chemotherapeutic agents. Testing ABCB1 expression or function is crucial for predicting therapy response and guiding drug selection. Key methods include qPCR, immunohistochemistry, and functional efflux assays. Main parameters assessed are ABCB1 mRNA/protein levels and transporter activity, informing personalized treatment strategies.

B-Raf Proto-Oncogene, Serine/Threonine Kinase

B-Raf Proto-Oncogene, Serine/Threonine Kinase is implicated in aberrant signaling pathways driving Esophageal Cancer progression. Testing its activity is crucial for evaluating therapeutic efficacy and guiding drug development. Our service employs ELISA, chemiluminescent, and ATP assays to quantify B-Raf kinase inhibition. Key parameters measured include MEC (Minimum Effective Concentration), MIC (Minimum Inhibitory Concentration), and IC-50 (half-maximal inhibitory concentration), providing comprehensive insights for targeted drug optimization.

Colony Stimulating Factor 1 Receptor

The Colony Stimulating Factor 1 Receptor (CSF1R) is implicated in esophageal cancer progression by promoting tumor-associated macrophage activity. CSF1R testing is vital for identifying and optimizing targeted therapies. Our service employs Bioluminescence Resonance Energy Transfer (BRET), chemiluminescent, and ATP assays to evaluate compound efficacy. The primary parameter measured is IC50, enabling precise assessment of drug potency against CSF1R for esophageal cancer drug development.

Cytotoxic T-Lymphocyte Associated Protein 4

Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) modulates immune response and is implicated in Esophageal Cancer immune evasion. CTLA-4 testing is vital for evaluating immunotherapy targets and drug efficacy. Our service utilizes flow cytometry, ELISA, and surface plasmon resonance assays to quantitatively assess CTLA-4 expression and drug interactions. Key parameters measured include binding affinity (Kd) and inhibitory concentration (IC-50), crucial for preclinical drug development and candidate selection.

Dna Topoisomerase I

DNA Topoisomerase I is a crucial enzyme involved in DNA replication and is often overexpressed in esophageal cancer, making it a key therapeutic target. Our testing service utilizes a chemiluminescent assay to evaluate drug candidates’ inhibitory effects on Topoisomerase I. The primary parameter measured is the Minimum Inhibitory Concentration (MIC), providing essential data for drug development and efficacy assessment in esophageal cancer therapies.

Epidermal Growth Factor Receptor

Epidermal Growth Factor Receptor (EGFR) is often overexpressed in esophageal cancer, driving tumor growth and progression. EGFR testing is vital for identifying targeted therapies and monitoring drug efficacy. Our service employs advanced methods such as FACS, DELFIA, chemiluminescent, HTRF, FRET, SPR, ELISA, and ATP assays. Key parameters measured include Ki, IC-50, MIC, Kd, pIC-50, and MEC, providing comprehensive data for esophageal cancer drug development.

Erb-B2 Receptor Tyrosine Kinase 2

Erb-B2 Receptor Tyrosine Kinase 2 (HER2/ERBB2) is frequently overexpressed in esophageal cancer, driving tumor growth and progression. Testing its activity is vital for drug development and targeted therapy assessment. Our service utilizes advanced techniques including FACS, chemiluminescent, flow cytometry, FRET, surface plasmon resonance, biolayer interferometry, and ELISA assays to evaluate key pharmacological parameters such as Ki, IC50, Kd, MIC, and MEC, supporting precise therapeutic development.

Fibroblast Growth Factor Receptor 1

Fibroblast Growth Factor Receptor 1 (FGFR1) is often overexpressed in esophageal cancer and drives tumor growth and survival. FGFR1 testing is crucial for identifying targeted therapy candidates and assessing drug efficacy. Our service utilizes ATP assay to measure cell viability in response to FGFR1 inhibitors, providing precise IC-50 values to evaluate compound potency. This enables efficient drug development and optimization for esophageal cancer treatments.

Fibroblast Growth Factor Receptor 2

Fibroblast Growth Factor Receptor 2 (FGFR2) drives tumor growth and progression in esophageal cancer, making it a critical therapeutic target. FGFR2 testing is essential for identifying and validating drug candidates that inhibit this pathway. Our service utilizes the ATP assay to assess compound efficacy, with IC-50 determination as the primary parameter, allowing precise quantification of inhibitor potency against FGFR2-driven esophageal cancer cell growth.

Programmed Cell Death 1

Programmed Cell Death 1 (PD-1) plays a crucial role in immune evasion in esophageal cancer, making it a key target in drug development. PD-1 testing is essential to evaluate therapeutic efficacy and immune modulation. We offer assays including FACS, flow cytometry, ELISA, chemiluminescence, HTRF, SPR, and competitive binding, using transfected CHO-K1 and Jurkat cells. Main parameters measured include EC-50, IC-50, Kd, and MIC, ensuring robust assessment of candidate drugs.

Receptor Interacting Serine/Threonine Kinase 2

Receptor Interacting Serine/Threonine Kinase 2 (RIPK2) is implicated in esophageal cancer progression by regulating inflammatory and cell death pathways. RIPK2 testing is vital for identifying and optimizing drug candidates targeting this kinase. Using chemiluminescent and ATP assays, our service precisely measures RIPK2 activity and inhibitor potency, with IC50 as the main parameter, enabling effective evaluation of therapeutic compounds for esophageal cancer drug development.